diagnost tool
global leader anim health diagnost
instrument lab test softwar sell direct
us addit mani countri outsid us
strong underpin strong global
execut reiter buy despit push-out snap
fecal rais pt
despit announc push snap fecal launch
quarter push-out make new workflow improv deliv strong
beat top bottom line rais adj ep guid rais
organ revenu growth outlook point driven robust
growth instrument previous guid attribut revenu lift
due adopt asu revenu contract custom
ad instrument recur revenu respect
vs model nevertheless new product intact posit trend strong global
commerci execut keep growth stori intact reiter buy rate rais
pt
result rev organ beat
beat everi revenu bucket largest beat vs estim
come instrument lab consumables/servic
strongest sourc growth came consumables/servic beat
instrument beat lab beat water beat
softwar beat adj ep y/i beat
 street sedivu strong unit gm
grew y/i beat om grew y/i
shi made invest lab oper
new program announc today roll new
program jan essenti cross-selling/bundl initi seek
multi-year commit year custom encourag greater adopt
modalti like chem hem urin lab rapid expect initi
strengthen cross-sel opportun come year
sdma-on-a-slid strong expect indic call
catalyst instal base clinic america adopt sdma-on-a-slid
disclos march great start consist
trajectori recent survey vet indic expect order
year hope mani base clinic america may
adopt year ship sedivu
guid rais organ growth revenu guid
reiter revenue guid rep
despit fact compani push snap fecal base
strong beat surmis may see addit upsid pro-forma basi
relat account chang rais adj ep guid two cent
rep fxn vs prior
chemistri place catalyst new america vs
vetscan new abaxi
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model rais revenu estim y/i
revenu estim rais
ep estim y/i ep forecast
y/i
macro report patient practic data patient practic revenu growth
y/i patient visit data y/i compar
step jibe survey data
well howev attribut step-down weather think soon call
trend watch close addit data topic
buy unchang target price may
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price may
diagnost tool
buy unchang target price may
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
pt use multipl adj ep y/i
pt use multipl new adj ep
pt use multipl revenu estim discount back year discount rate
lower pt use multipl prior revenu estim discount back year
discount rate pt suggest price-to-earnings multipl ep estim
risk achiev target price valuat
valuat trade continu trade meaning premium us healthcar compani compani
 result guarante continu trade higher even abl exceed guidanc
util anim health underli demand anim health patient offic visit strong steadi year idexx
could see pressur event underli anim health util reach peak level turn could impli difficult
econom pressur unemploy rate tick lower rel level seen great recess variou
macroeconom headwind could reduc demand diagnost pet servic econom weak could caus pet owner skip
defer visit vet hospit could affect owner willing approv certain diagnost test compli treatment plan
even continu own pet
larg intern exposur deriv revenu outsid north america intern growth rate
commonli exceed unit state guarante occur futur believ intern growth
volatil growth rate us addit currenc fluctuat intern sale may continu
advers impact revenu earn
competit competit veterinari diagnost market high time intens although vet diagnost market
less duopoli compani compet commerci clinic lab hospit clinic lab manufactur multi-test blood
analyz on-sit test system expect competit abaxi particular remain rel high
regulatori risk product subject usda foreign regulatori agenc respect product
approv manufactur market promot label record keep test qualiti storag product dispos howev
regulatori risk lower human medic compani
competit competit human veterinari diagnost market intens may intensifi though abaxi primari vet
marketplac current duopoli vet market abaxi compet industri titan seen rise
competit activ third largest player
buy unchang target price may
diagnost tool
variabl order pattern guidanc abaxi busi lumpi depend pace distributor order
make forecast quarter difficult result manag chosen provid guidanc result lack
visibl may result wide rang consensu estim
econom sensit abax revenu function sell anim health clinic predominantli bill pet owner
self-pay basi macroeconomic activ employ wage home valu result chang pet owner budget
anim health industri sticki econom recess would neg impact abax busi
hska ev/rev multipl expand year ago discount idxx slight
premium abax slowdown us economi anim health util could slow revenu margin growth
particularli given industri almost self-pay small penetr health plan insur competit
abax particularli abax idexx replic strategi mirror chang distributor relationship
contribut new samsung instrument launch risk associ busi
oversea execut build ou busi consum price time new product launch abil innov
keep industri leader fewer capit resourc smaller compani risk rel competitor
oper refer lab offer product certain new product categori autom urinalysi sdma name two
thu present posit cross-sel across product well industry-lead abil maintain
expand us market share strong competitor innov introduc signific new product launch
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
